Publication details
30 let inhibice systému renin-angiotensin-aldosteron u srdečního selhání
| Title in English | Thirty years of renin-angiotensin-aldosterone system inhibition in chronic heart failure |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Article in Periodical |
| Magazine / Source | Kardiologická revue - Interní medicína |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | chronic heart failure; ace inhibitors; angiotensin receptor blockers; mineralocorticoid receptor antagonists; aliskiren; omapatrilat; sacubitril/ valsartan |
| Description | The paper presents a historical overview of mortality trials on angiotensin-aldosterone system inhibition in patients with chronic heart failure. From the CONSENSUS trial up to the PARADIGM-HF trial it has been shown that ACE inhibitors/ angiotensin II receptor antagonists (AT1-blockers, ARBs, sartans) along with mineralocorticoid receptor blockers, have been the gold standard of treatment. Both direct renin blocker aliskiren and dual blocker enalapril + neprilysin inhibitor proved ineffective; on the other hand, the new dual angiotensin II receptor blocker + neprilysin inhibitor - sacubitril-valsartan is a new therapeutic combination for future treatment of chronic heart failure. |